文献速递免疫规划传染病防控与疫情报告

新型改良安卡拉痘苗病毒载体RSV疫苗的安全性与免疫原性:一项随机I期临床试验

Safety and immunogenicity of novel modified vaccinia Ankara-vectored RSV vaccine: A randomized phase I clinical trial.
PubMed 文献 · Vaccine · 2020-02-11

这项首次人体随机I期试验将63名成人(18-49岁)和老年人(50-65岁)分配到低剂量(1×10^7 TCID50)或高剂量(1×10^8 TCID50)MVA-BN-RSV疫苗组,按6:1随机接受2剂疫苗或安慰剂(间隔4周),监测30周。疫苗耐受性良好,未报告严重不良事件,诱导了广泛的细胞和体液免疫应答,高剂量组应答更强更广,支持进一步开发。

要点

  • MVA-BN-RSV候选疫苗耐受性良好,未报告严重不良事件或特殊关注不良事件。
  • 高剂量组对至少3个肽池的应答者比例为83%,低剂量组为63%。
  • 高剂量组针对RSV A和B亚型的体液应答最高约2倍升高,成人组与老年组间无差异。

核心结论

  • MVA-BN-RSV候选疫苗耐受性良好,可诱导广泛的细胞和体液免疫应答,支持进一步开发。

研究设计与样本

  • 首次人体随机I期临床试验,63名参与者分为3组:成人(18-49岁)低剂量(1×10^7 TCID50)或高剂量(1×10^8 TCID50)组,以及老年人(50-65岁)高剂量组。
  • 每组参与者按6:1比例随机接受2剂MVA-BN-RSV或安慰剂,间隔4周,监测30周;所有参与者均完成研究并接受两剂接种。

主要发现

  • 未报告严重不良事件或特殊关注不良事件;最常见不良事件为注射部位疼痛,合并高剂量组为56%,低剂量组为17%。
  • MVA-BN-RSV诱导覆盖全部5个插入片段的稳健T细胞应答,倍数增加范围为1.8至3.8。
  • 高剂量组观察到更高更广的应答:合并高剂量组对至少3个肽池的应答者比例为83%,低剂量组为63%。
  • 针对RSV A和B亚型观察到中等但一致的体液应答,高剂量组最高约2倍升高。
  • 成人组与老年组在安全性、反应原性或免疫原性方面未观察到差异。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Respiratory disease caused by RSV infection is recognized as a severe public health issue in infants, young children and elderly with no specific treatment option. Vaccination may be the most effective strategy to combat this highly infectious virus although no vaccine has been approved. The novel vaccine candidate MVA-BN-RSV encodes RSV surface proteins F and G (subtypes A, B) as well as internal proteins N and M2 in the MVA-BN viral vector backbone to provide broad protection against RSV. This was a first in human study to investigate safety, reactogenicity and immunogenicity of MVA-BN-RSV. Sixty-three participants were allocated to 3 groups: adult (18-49 years) low (1 × 107 TCID50) or high (1 × 108 TCID50) dose and older adult (50-65 years) high dose. Participants in each group were randomized in a 6:1 ratio to receive 2 doses of MVA-BN-RSV or placebo 4 weeks apart and were monitored for 30 weeks. All participants completed the study, receiving both doses. No serious AEs or AEs of special interest were reported. The most common AEs were injection site pain (56% in the combined high dose groups, 17% in the low dose group). MVA-BN-RSV induced robust T cell responses covering all 5 inserts with fold increases ranging from 1.8 to 3.8. Higher and broader responses were observed in the high dose groups (83% responders to at least 3 peptide pools in the combined high dose groups compared to 63% in the low dose group). Moderate but consistent humoral responses were observed against A and B RSV subtypes (up to approximately 2-fold increases in the high dose groups). No differences were observed between the adult and the older adult groups in safety, reactogenicity or immunogenicity. The study demonstrated that the well tolerated MVA-BN-RSV vaccine candidate induces broad cellular and humoral immune responses, warranting further development.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Samy N, Reichhardt D, Schmidt D, et al. Safety and immunogenicity of novel modified vaccinia Ankara-vectored RSV vaccine: A randomized phase I clinical trial. Vaccine. 2020. PMID: 32057576. doi:10.1016/j.vaccine.2020.01.055

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。